RxDoctor Payments Data

Rebecca Lopez

Family · El Paso, TXNPI 1336777911

Payments from drug & device makers

$3,948in general payments, 2019–2025

Across 118 payments — averaging $33.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Axonics, Inc.$1K
  • AstraZeneca$206
  • GSK$202
  • Novo Nordisk$199
  • Lilly USA, LLC$175
  • plus $712 from 13 others

What the payments were for

  • Travel & lodging$1,73244%
  • Food & beverage$2,14354%
  • Education$742%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,948 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$18,063
Medicare patients
96
Services billed
327

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron166$93,734
MyrbetriqMirabegron120$69,982
Estradiol264$19,976
Methenamine Hippurate171$13,512
Mirabegron ErMirabegron26$8,846
OsphenaOspemifene20$6,496
VeozahFezolinetant11$6,246
Tolterodine Tartrate ErTolterodine Tartrate23$2,859
Solifenacin Succinate77$2,855
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst105$1,625
ProgesteroneProgesterone, Micronized82$913
LyllanaEstradiol12$890
Bethanechol Chloride42$879
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip28$719
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav67$501

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq, Veozah$145$76,228131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 15,456 family providers in Texas.

Other family in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →